

Emanuele Azzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4584592/publications.pdf>

Version: 2024-02-01

27
papers

2,430
citations

687363

13
h-index

752698

20
g-index

28
all docs

28
docs citations

28
times ranked

4952
citing authors

#	ARTICLE	IF	CITATIONS
1	One Size Does Not Fit All: Heterogeneity in Developmental Hematopoiesis. <i>Cells</i> , 2022, 11, 1061.	4.1	7
2	KIT is dispensable for physiological organ vascularisation in the embryo. <i>Angiogenesis</i> , 2022, 25, 343-353.	7.2	8
3	Editorial: Fetal/Embryonic Hematopoietic Progenitors and Their Impact on Adult Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 732649.	3.7	2
4	Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors. <i>Nature Communications</i> , 2021, 12, 7019.	12.8	8
5	The onset of circulation triggers a metabolic switch required for endothelial to hematopoietic transition. <i>Cell Reports</i> , 2021, 37, 110103.	6.4	17
6	Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 618164.	3.7	14
7	Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells. <i>Blood</i> , 2018, 131, 2223-2234.	1.4	17
8	Kit ligand has a critical role in mouse yolk sac and aortaâ€“gonadâ€“mesonephros hematopoiesis. <i>EMBO Reports</i> , 2018, 19, .	4.5	35
9	Definitive EMP and Pre-HSC Emerge in Myb-Null Murine Embryos and Retain Macrophage Potential. <i>Blood</i> , 2018, 132, 2556-2556.	1.4	1
10	Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors. <i>PLoS ONE</i> , 2016, 11, e0164893.	2.5	5
11	Embryonic hematopoietic progenitors depend on kit ligand for in vivo expansion and differentiation. <i>Experimental Hematology</i> , 2016, 44, S43.	0.4	0
12	Definitive erythro-myeloid progenitors (EMP) with macrophage-restricted lineage potential emerge in Myb-null murine embryos. <i>Experimental Hematology</i> , 2016, 44, S93.	0.4	0
13	Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors. <i>Nature Immunology</i> , 2016, 17, 1424-1435.	14.5	49
14	Embryonic thymopoiesis is initiated by an immune-restricted lympho-myeloid progenitor independently of notch signaling. <i>Experimental Hematology</i> , 2016, 44, S65.	0.4	0
15	Pathways regulating the endothelial-to-hematopoietic transition. <i>Experimental Hematology</i> , 2016, 44, S29.	0.4	0
16	Hematopoietic Reprogramming InÂVivo Informs InÂVivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells. <i>Developmental Cell</i> , 2016, 36, 525-539.	7.0	34
17	Tissue-resident macrophages originate from yolk sac-derived erythro-myeloid progenitors. <i>Experimental Hematology</i> , 2015, 43, S64.	0.4	18
18	Exploring the role of kit ligand at the onset of hematopoiesis. <i>Experimental Hematology</i> , 2015, 43, S51.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. <i>Nature</i> , 2015, 518, 547-551.	27.8	1,724
20	Direct conversion from mouse fibroblasts informs the identification of hemogenic precursor cells in vivo. <i>Experimental Hematology</i> , 2014, 42, S55.	0.4	0
21	Hemogenic endothelium generates mesoangioblasts that contribute to several mesodermal lineages <i>in vivo</i> . <i>Development (Cambridge)</i> , 2014, 141, 1821-1834.	2.5	42
22	A short history of hemogenic endothelium. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 206-212.	1.4	62
23	Lymphomyeloid Contribution of an Immune-Restricted Progenitor Emerging Prior to Definitive Hematopoietic Stem Cells. <i>Cell Stem Cell</i> , 2013, 13, 535-548.	11.1	225
24	Hemogenic endothelium generates mesoangioblasts that contribute to several mesodermal lineages in vivo. <i>Experimental Hematology</i> , 2013, 41, S24.	0.4	0
25	Nitric Oxide Sustains Long-Term Skeletal Muscle Regeneration by Regulating Fate of Satellite Cells Via Signaling Pathways Requiring Vangl2 and Cyclic GMP. <i>Stem Cells</i> , 2012, 30, 197-209.	3.2	91
26	A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. <i>Pharmacological Research</i> , 2011, 64, 210-217.	7.1	36
27	Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. <i>British Journal of Pharmacology</i> , 2010, 160, 1550-1560.	5.4	35